S&P 500   3,941.26 (-1.44%)
DOW   33,596.34 (-1.03%)
QQQ   281.68 (-2.07%)
AAPL   142.91 (-2.54%)
MSFT   245.12 (-2.03%)
META   114.12 (-6.79%)
GOOGL   96.98 (-2.51%)
AMZN   88.25 (-3.03%)
TSLA   179.82 (-1.44%)
NVDA   159.87 (-3.75%)
NIO   13.24 (+3.44%)
BABA   91.45 (+1.03%)
AMD   70.27 (-4.55%)
T   19.17 (+2.24%)
MU   53.68 (-0.67%)
CGC   3.61 (-16.44%)
F   13.28 (-0.75%)
GE   85.28 (+0.73%)
DIS   92.29 (-3.79%)
AMC   6.75 (-9.40%)
PYPL   72.23 (-1.89%)
PFE   49.71 (-2.01%)
NFLX   305.56 (-2.25%)
S&P 500   3,941.26 (-1.44%)
DOW   33,596.34 (-1.03%)
QQQ   281.68 (-2.07%)
AAPL   142.91 (-2.54%)
MSFT   245.12 (-2.03%)
META   114.12 (-6.79%)
GOOGL   96.98 (-2.51%)
AMZN   88.25 (-3.03%)
TSLA   179.82 (-1.44%)
NVDA   159.87 (-3.75%)
NIO   13.24 (+3.44%)
BABA   91.45 (+1.03%)
AMD   70.27 (-4.55%)
T   19.17 (+2.24%)
MU   53.68 (-0.67%)
CGC   3.61 (-16.44%)
F   13.28 (-0.75%)
GE   85.28 (+0.73%)
DIS   92.29 (-3.79%)
AMC   6.75 (-9.40%)
PYPL   72.23 (-1.89%)
PFE   49.71 (-2.01%)
NFLX   305.56 (-2.25%)
S&P 500   3,941.26 (-1.44%)
DOW   33,596.34 (-1.03%)
QQQ   281.68 (-2.07%)
AAPL   142.91 (-2.54%)
MSFT   245.12 (-2.03%)
META   114.12 (-6.79%)
GOOGL   96.98 (-2.51%)
AMZN   88.25 (-3.03%)
TSLA   179.82 (-1.44%)
NVDA   159.87 (-3.75%)
NIO   13.24 (+3.44%)
BABA   91.45 (+1.03%)
AMD   70.27 (-4.55%)
T   19.17 (+2.24%)
MU   53.68 (-0.67%)
CGC   3.61 (-16.44%)
F   13.28 (-0.75%)
GE   85.28 (+0.73%)
DIS   92.29 (-3.79%)
AMC   6.75 (-9.40%)
PYPL   72.23 (-1.89%)
PFE   49.71 (-2.01%)
NFLX   305.56 (-2.25%)
S&P 500   3,941.26 (-1.44%)
DOW   33,596.34 (-1.03%)
QQQ   281.68 (-2.07%)
AAPL   142.91 (-2.54%)
MSFT   245.12 (-2.03%)
META   114.12 (-6.79%)
GOOGL   96.98 (-2.51%)
AMZN   88.25 (-3.03%)
TSLA   179.82 (-1.44%)
NVDA   159.87 (-3.75%)
NIO   13.24 (+3.44%)
BABA   91.45 (+1.03%)
AMD   70.27 (-4.55%)
T   19.17 (+2.24%)
MU   53.68 (-0.67%)
CGC   3.61 (-16.44%)
F   13.28 (-0.75%)
GE   85.28 (+0.73%)
DIS   92.29 (-3.79%)
AMC   6.75 (-9.40%)
PYPL   72.23 (-1.89%)
PFE   49.71 (-2.01%)
NFLX   305.56 (-2.25%)
NASDAQ:ALNY

Alnylam Pharmaceuticals - ALNY Stock Forecast, Price & News

$219.64
-6.56 (-2.90%)
(As of 12/6/2022 12:00 AM ET)
Add
Compare
Today's Range
$215.28
$226.27
50-Day Range
$185.11
$234.40
52-Week Range
$117.58
$236.80
Volume
425,355 shs
Average Volume
910,962 shs
Market Capitalization
$27.02 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$232.37

Alnylam Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.68 Rating Score
Upside/​Downside
5.7% Upside
$232.37 Price Target
Short Interest
Healthy
4.52% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.52
Upright™ Environmental Score
News Sentiment
0.63mentions of Alnylam Pharmaceuticals in the last 14 days
Based on 9 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($9.66) to ($5.58) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.19 out of 5 stars

Medical Sector

402nd out of 1,023 stocks

Pharmaceutical Preparations Industry

175th out of 501 stocks

ALNY stock logo

About Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Receive ALNY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alnylam Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ALNY Stock News Headlines

What 12 Analyst Ratings Have To Say About Alnylam Pharmaceuticals
See More Headlines
Receive ALNY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alnylam Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ALNY Company Calendar

Last Earnings
10/27/2022
Today
12/06/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/09/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:ALNY
CUSIP
02043Q10
Employees
1,665
Year Founded
2002

Price Target and Rating

Average Stock Price Forecast
$232.37
High Stock Price Forecast
$415.00
Low Stock Price Forecast
$145.00
Forecasted Upside/Downside
+5.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.68
Research Coverage
19 Analysts

Profitability

Net Income
$-852,820,000.00
Net Margins
-123.02%
Pretax Margin
-122.83%

Debt

Sales & Book Value

Annual Sales
$844.29 million
Book Value
$4.92 per share

Miscellaneous

Free Float
121,306,000
Market Cap
$27.02 billion
Optionable
Optionable
Beta
0.54

Social Links


Key Executives

  • Mr. Michael W. Bonney B.A. (Age 64)
    Exec. Chairman
    Comp: $317.97k
  • Dr. Yvonne L. Greenstreet M.B.A. (Age 59)
    MBA, MBChB, CEO & Director
    Comp: $1.23M
  • Dr. Akshay K. Vaishnaw M.D. (Age 59)
    Ph.D., Pres
    Comp: $1.09M
  • Mr. Jeffrey V. Poulton M.B.A. (Age 54)
    CFO & Exec. VP
    Comp: $914.05k
  • Mr. Tolga Tanguler M.B.A.Mr. Tolga Tanguler M.B.A.
    Exec. VP & Chief Commercial Officer
  • Dr. Alfred W. Boyle Ph.D.
    Chief Technical Operations & Quality Officer
  • Dr. Kevin Joseph Fitzgerald Ph.D. (Age 54)
    Sr. VP, Head of Research & Chief Scientific Officer
  • Ms. Christine Regan Lindenboom
    Sr. VP of Investor Relations & Corp. Communications
  • Ms. Indrani M. Lall Franchini J.D. (Age 50)
    Exec. VP, Chief Legal Officer & Sec.
  • Mr. Piyush Sharma J.D.
    Chief Ethics & Compliance Officer













ALNY Stock - Frequently Asked Questions

Should I buy or sell Alnylam Pharmaceuticals stock right now?

19 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Alnylam Pharmaceuticals in the last year. There are currently 6 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ALNY shares.
View ALNY analyst ratings
or view top-rated stocks.

What is Alnylam Pharmaceuticals' stock price forecast for 2023?

19 equities research analysts have issued 1 year price objectives for Alnylam Pharmaceuticals' shares. Their ALNY share price forecasts range from $145.00 to $415.00. On average, they anticipate the company's stock price to reach $232.37 in the next twelve months. This suggests a possible upside of 6.3% from the stock's current price.
View analysts price targets for ALNY
or view top-rated stocks among Wall Street analysts.

How have ALNY shares performed in 2022?

Alnylam Pharmaceuticals' stock was trading at $169.58 on January 1st, 2022. Since then, ALNY shares have increased by 29.0% and is now trading at $218.68.
View the best growth stocks for 2022 here
.

Are investors shorting Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals saw a decrease in short interest during the month of November. As of November 15th, there was short interest totaling 5,560,000 shares, a decrease of 7.8% from the October 31st total of 6,030,000 shares. Based on an average trading volume of 970,700 shares, the short-interest ratio is currently 5.7 days.
View Alnylam Pharmaceuticals' Short Interest
.

When is Alnylam Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 9th 2023.
View our ALNY earnings forecast
.

How were Alnylam Pharmaceuticals' earnings last quarter?

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) issued its quarterly earnings data on Thursday, October, 27th. The biopharmaceutical company reported ($3.32) EPS for the quarter, missing the consensus estimate of ($1.77) by $1.55. The biopharmaceutical company had revenue of $264.31 million for the quarter, compared to analysts' expectations of $291.81 million. Alnylam Pharmaceuticals had a negative net margin of 123.02% and a negative trailing twelve-month return on equity of 430.74%. The firm's revenue was up 40.9% compared to the same quarter last year. During the same quarter last year, the firm posted ($1.72) earnings per share.

What guidance has Alnylam Pharmaceuticals issued on next quarter's earnings?

Alnylam Pharmaceuticals updated its FY 2022 earnings guidance on Thursday, November, 3rd. The company provided EPS guidance of for the period. The company issued revenue guidance of $970.00M-$1.08 billion, compared to the consensus revenue estimate of $1.07 billion.

What is John M. Maraganore's approval rating as Alnylam Pharmaceuticals' CEO?

65 employees have rated Alnylam Pharmaceuticals Chief Executive Officer John M. Maraganore on Glassdoor.com. John M. Maraganore has an approval rating of 99% among the company's employees. This puts John M. Maraganore in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Alnylam Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alnylam Pharmaceuticals investors own include Alibaba Group (BABA), NVIDIA (NVDA), XOMA (XOMA), Ionis Pharmaceuticals (IONS), Gilead Sciences (GILD), NXP Semiconductors (NXPI), Mylan (MYL), AbbVie (ABBV), Micron Technology (MU) and Advanced Micro Devices (AMD).

What is Alnylam Pharmaceuticals' stock symbol?

Alnylam Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALNY."

Who are Alnylam Pharmaceuticals' major shareholders?

Alnylam Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Nuveen Asset Management LLC (13.49%), Vanguard Group Inc. (8.98%), Baillie Gifford & Co. (7.93%), BlackRock Inc. (6.23%), Price T Rowe Associates Inc. MD (3.02%) and State Street Corp (2.27%). Insiders that own company stock include Akshay Vaishnaw, Barry E Greene, Jeffrey W Dunn, John Maraganore, Laurie Keating, Phillip A Sharp, Steven M Paul, Tolga Tanguler and Yvonne Greenstreet.
View institutional ownership trends
.

How do I buy shares of Alnylam Pharmaceuticals?

Shares of ALNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Alnylam Pharmaceuticals' stock price today?

One share of ALNY stock can currently be purchased for approximately $218.68.

How much money does Alnylam Pharmaceuticals make?

Alnylam Pharmaceuticals (NASDAQ:ALNY) has a market capitalization of $26.90 billion and generates $844.29 million in revenue each year. The biopharmaceutical company earns $-852,820,000.00 in net income (profit) each year or ($9.77) on an earnings per share basis.

How many employees does Alnylam Pharmaceuticals have?

The company employs 1,665 workers across the globe.

How can I contact Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals' mailing address is 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE, CAMBRIDGE MA, 02142. The official website for the company is www.alnylam.com. The biopharmaceutical company can be reached via phone at (617) 551-8200, via email at investors@alnylam.com, or via fax at 617-551-8101.

This page (NASDAQ:ALNY) was last updated on 12/6/2022 by MarketBeat.com Staff